Navigation Links
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
Date:4/30/2008

- Final study report expected in June 2008 -

MORRISTOWN, N.J., April 30 /PRNewswire/ -- Vicus Therapeutics, LLC, a biopharmaceutical company focused on oncology supportive care, announced today the completion of the last patient visit in its study VT1-CAX-001, a Phase 2 trial of VT-122. The compound was tested for the treatment of cachexia in weight losing subjects with Stage IV, non-small cell lung cancer (NSCLC). The Phase 2 clinical trial was conducted in India and the final study report is expected in June 2008.

A total of 59 subjects were deemed eligible for this multi-center, randomized, open-label controlled Phase 2 study in weight losing Stage IV NSCLC patients not on chemotherapy. The 12 subjects randomized to the control arm received best supportive care and the 25 subjects randomized to the treatment arms received best supportive care and one of two doses of VT-122. Twenty-two of the screened subjects were not randomized. The primary efficacy endpoints assessed were maintenance of muscle mass (lean body mass) and function (grip strength). Efficacy endpoints of total body weight and quality of life were also assessed. Assessments for safety and efficacy were continued for 12 weeks after randomization. No treatment related serious adverse events were reported.

"The successful completion of the Phase 2 study marks an important milestone in the development of VT-122," said John Maki, President and Chief Executive Officer of Vicus Therapeutics. "Based on favorable analysis of the preliminary data, we expect to initiate discussions with prospective partners to secure resources to maximize the potential of VT-122."

About Cachexia and VT-122

Cachexia is a debilitating, progressive muscle wasting condition manifested by unintentional weight loss, muscle weakness, anemia, fatigue, and death. In advanced cancer patients, the prevalence of cachexia increases from 50% at diagnosis to more than 80% prior to death. There is currently no FDA-approved therapy for treating cancer cachexia.

VT-122 is an oral, multi-targeted, chrono-modulated, fixed dose combination of propranolol and etodolac. Vicus chose the constituent drugs based on the results of its cancer cachexia disease model that predicted blocking systemic inflammation would reverse the wasting process. The use of this combination was initially assessed in investigator-led pilot trials. Data obtained from a total of nine evaluable subjects demonstrated reversal of rapid weight loss in seven subjects. No treatment related serious adverse events were reported.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held biopharmaceutical company focused on developing oncology supportive care drug products for serious unmet medical needs. These products include: VT-122, in Phase 2 clinical trials, for cancer cachexia; VT-211 and VT-212, in investigator-led pilot trials, for chemotherapy-induced oral mucositis and neutropenia; and VT-310, in pre-clinical evaluation, for cancer-related fatigue. Each product candidate is a novel combination and dosing regimen of two generic drugs with known safety profiles. The constituent drugs and dosing regimens are chosen based on the results of Vicus' predictive disease models and the company's understanding of the body's maladaptive response to cancer and its treatment.

Website: http://www.vicustherapeutics.com


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
3. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
7. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
11. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... Heart Association/American Stroke Association's Get With The Guidelines®-Stroke Gold Plus Achievement Award ... a second for Memorial Healthcare System, recognizes its commitment to emergency stroke ...
(Date:5/25/2016)... , ... May 25, 2016 , ... The Georgia State ... of Excellence from the Atlanta Urban Design Commission. , The annual award recognizes projects, ... of Atlanta’s built environment, the preservation of its physical heritage and the balance between ...
(Date:5/25/2016)... ... May 25, 2016 , ... A new update to ... to motion capture, all by utilizing a common Wi-Fi network and a mobile device. ... data from any location with Wi-Fi, and use a mobile device to control the ...
(Date:5/25/2016)... ... May 25, 2016 , ... One Florida-based plastic surgeon’s enthusiasm is ... an article published May 13th on Vanity Fair. In fact, as the ... of their procedures broadcast to more than 800,000 Snapchat fans. Commenting on this trend, ...
(Date:5/25/2016)... , ... May 25, 2016 , ... The Bank of ... Biomedical Technology Program to help provide veterans a pathway to employment and successful careers ... a $20,000 check to Nick Hallack, President and CEO of Medisend, parent organization and ...
Breaking Medicine News(10 mins):